Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of IBI3042 in Healthy Adult Participants

Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing Investigational Drug: IBI3042 with Matching Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events at 29 days, Number of Participants With Clinically Significant Abnormal Vital Signs at 29 days and 3 more. Planned start Sep 2026; status: not yet recruiting.